Insider Transactions in Q4 2025 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2025
|
Brian Piekos Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,471
-29.81%
|
$58,123
$13.45 P/Share
|
|
Nov 24
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,940
-2.56%
|
$142,220
$13.45 P/Share
|
|
Nov 24
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,296
-3.86%
|
$68,848
$13.45 P/Share
|
|
Nov 24
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
4,331
-1.9%
|
$56,303
$13.45 P/Share
|
|
Nov 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.52%
|
-
|
|
Nov 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+1.35%
|
-
|
|
Nov 21
2025
|
Brian Piekos Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Nov 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+5.16%
|
-
|
|
Nov 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.52%
|
-
|
|
Nov 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+1.64%
|
-
|
|
Nov 20
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
87,390
+28.34%
|
-
|
|
Nov 18
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,075
-2.38%
|
$43,050
$14.48 P/Share
|
|
Nov 18
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,683
-1.97%
|
$37,562
$14.48 P/Share
|
|
Nov 18
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,466
-1.09%
|
$62,524
$14.48 P/Share
|
|
Nov 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+4.76%
|
-
|
|
Nov 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+2.99%
|
-
|
|
Nov 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,364
+2.24%
|
-
|
|
Nov 12
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,328
-0.83%
|
$36,608
$11.55 P/Share
|
|
Nov 11
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,120
+1.74%
|
-
|